Male Breast Cancer: A Multicentric Study

Culell, Pere; Solernou, Lluís; Tarazona, Jordi; Roma, Jordi Casas; Martí, Elena; Miguel, Ana; Buxó, J; Yanguas, Carlos; Badal, Josep

doi:10.1111/j.1524-4741.2007.00412.x

Cited by 19 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer in men accounts for less than 1% of breast cancer diagnoses in the United States [ 10 ]. Breast cancer in men is a rare malignant tumor that represents less than 0.2% of all cancers in humans and less than 1% of breast cancers [ 1 , 2 ]. Our study shows that breast cancer occurs in young adult men.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, genetic counseling should be offered in each case. It is not rare to have bilateral breast cancer, although not as common as unilateral in men [ 1 ]. Indeed, we only found one case of bilateral localization.…”

Section: Discussionmentioning

confidence: 99%

“…Human breast cancer is a rare malignant tumor that accounts for less than 0.2% of all human cancers and less than 1% of breast cancers [ 1 , 2 ]. However, its incidence has increased over the past 25 years as the world's population ages [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…However, its incidence has increased over the past 25 years as the world's population ages [ 3 , 4 ]. Although its etiology is still little known because of its rarity, current knowledge incriminates the constitutional, environmental, hormonal (estrogen/androgen balance), and genetic risk factors (family history, Klinefelter syndrome, gene mutations BRCA1, and especially BRCA2) [ 1 , 4 , 5 ]. It generally occurs in elderly subjects and is associated with a poor prognosis because of an often late diagnosis [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Male Breast Cancer in Togo: Imaging and Clinicopathological Findings

Darré

Tchaou

Djiwa

et al. 2020

International Journal of Breast Cancer

View full text Add to dashboard Cite

Background. Breast cancer in men is a rare condition, often diagnosed late. The purpose of this study was to describe its epidemiological, histopathological, and radiographic aspects in Togo. Materials and Methods. This was a descriptive retrospective study on cases of breast cancer in humans diagnosed histologically at the Laboratory of Anatomy Pathological and Imagery of the University Hospital in Lomé, over a period of 25 years (1995 to 2019). The parameters studied were epidemiological, anatomopathological, and imaging. Results. Eighty-two (82) cases were diagnosed, an annual frequency of 3.28 cases. The mean age was 45±2.5 years; the range was 27-63 years. The family history of 47 patients (57.32%) was known. Carcinomas represented the predominant histological group with predominantly nonspecific invasive carcinoma (87.5%). These cancers were diagnosed at late stages (75.71% grade II). They were mainly of luminal B profile (38.75%) and associated with mutations of the BRCA2 and BRCA1 genes in 14.63% of the cases. The lesions were classified ACR 5 in 61.5% (11/18). Two cases of breast angiosarcoma were diagnosed by the identification of CD31 markers and factor VIII in immunohistochemistry. Hormone therapy such as tamoxifen was prescribed in all luminal patients (43 patients). Radiotherapy was administered to 15 patients (18.3%), with acute toxicity in 20% of the cases. After a median follow-up of 36 months, the evolution was complete remission in 27 patients (32.93%). Conclusion. Breast cancer in men is rare, often diagnosed late with a poor prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Male Breast Cancer in Togo: Imaging and Clinicopathological Findings

Darré

Tchaou

Djiwa

et al. 2020

International Journal of Breast Cancer

View full text Add to dashboard Cite

show abstract

“…Although the treatment efficacy between men and women may be inconsistent in many aspects due to biological differences, strategies gleaned from cases of female breast cancer may be helpful [ 3 ]. Therefore, curative surgical resection followed by adjuvant chemotherapy is regarded as a standard treatment for non-metastatic male breast cancer, and adjuvant treatment, which includes chemotherapeutic agents and endocrine therapy in hormone receptor-positive cases, is similar to that for female breast cancer [ 4 5 6 ].…”

Section: Introductionmentioning

confidence: 99%

The Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Relapsed Ectopic Male Breast Cancer

et al. 2020

View full text Add to dashboard Cite

Ectopic male breast cancer is very rare. Consequently, there is a lack of prospective clinical trials, and most recommendations for treatment are based on the experiences of clinicians and data from female breast cancer patients. The United States Food and Drug Administration has recently approved palbociclib combined with endocrine therapy for advanced male breast cancer because of the positive results of its use in metastatic female breast cancer. Therefore, it is worth considering cyclin-dependent kinase 4/6 inhibitors as alternatives to conventional chemotherapies for advanced male breast cancer patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative cancers. The present case report introduces the use of palbociclib plus letrozole as first-line therapy for an elderly male patient with relapsed ectopic breast cancer, notwithstanding the limitations of the current national health insurance policy.

show abstract

A contemporary review of male breast cancer: current evidence and unanswered questions

Leon‐Ferre

Giridhar

Hieken

et al. 2018

Cancer Metastasis Rev

View full text Add to dashboard Cite

Male breast cancer is rare, accounting for 1% of all breast cancer diagnoses in the USA. Because of its rarity, most major breast cancer trials have included only female patients. This has resulted in limited prospective data to guide the clinical management of men with breast cancer. As a result, treatment decisions are typically extrapolated from data generated in female patients. This approach may be suboptimal, particularly considering the differing hormonal milieus between men and women with respect to both breast cancer development and treatment. Herein, we summarize current knowledge of the biology and clinicopathology of male breast cancer and review current approaches to locoregional and systemic management of this rare disease.

show abstract

Male Breast Cancer: A Multicentric Study

Cited by 19 publications

References 13 publications

Male Breast Cancer in Togo: Imaging and Clinicopathological Findings

Male Breast Cancer in Togo: Imaging and Clinicopathological Findings

The Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Relapsed Ectopic Male Breast Cancer

A contemporary review of male breast cancer: current evidence and unanswered questions

Contact Info

Product

Resources

About